Conference Description

October 13-14, 2007
Renaissance Dallas
2222 Stemmons Freeway
Dallas, TX
214-631-2222

Tell a friend about this conference

Download the brochure for this conference

See how attendees evaluated this conference.

CME Credits: 10.0*

Nonrefundable registration fee: $0.

Target Audience: Physicians, Nurse Practitioners, and Physician Assistants.

Program Summary:

This program will provide Primary Care Physicians the opportunity to learn first hand from national thought leaders in their field. The goal is to provide a clearer understanding of several of the most common disease processes, in light of rapid scientific advances. By doing so, attendees will walk away with new insights and learn useful strategies to manage the challenges faced on a daily basis. This program will incorporate didactic lectures, case based learning, and utilize an audience response system to facilitate discussion among participants to enhance the educational opportunity.

Learning Objectives:
At the conclusion of this program, participants should be able to:

1. understand the role of immune response modifiers in the treatment of warts; appreciate the mechanisms of action and efficacy of anti-inflammatory dose doxycycline in acne rosacea, and learn appropriate use of topical steroids and calcipotriene for the treatment of psoriasis
2. appreciate that given its favorable risk to benefit ratio, the more widespread and appropriate aggressive management of patients with statins will confer statistically significant and clinically important reductions in myocardial infarction, stroke, and deaths from cardiovascular disease
3. review early pathogenesis and prevention of type 2 diabetes, more effectively attain tight glucose control and discuss recent outcomes trials on the develop - ment and progression of atherosclerosis in diabetes
4. review glycemic and cardiovascular outcomes from insulin trials in type 2 diabetes, and optimize glycemic control with insulin in type 2 diabetes while minimizing weight gain and hypoglycemia
5. appreciate recent advances in our understanding of the neurobiology of sleep-wake regulation, and understand behavioral and pharmacological approaches to insomnia including their application in the clinical setting
6. utilize diagnostic criteria for Restless Leg Syndrome, understand recent advances in the pathophysiology of the disease, utilize current behavioral and pharmacologic treatment options to reduce symptoms and increase quality of life
7. more quickly and effectively recognize and diagnose cognitively impaired patients with increased understanding of the pathology of dementia and evolving treatment strategies
8. identify key differences between constipation predominant irritable bowel syndrome and chronic constipation, recognize worrisome signs and symptoms warranting referral, and understand the latest therapeutic options
9. recognize the underlying pathophysiology of BPH, utilize the AUA scoring system and choose appro - priate pharmacotherapy and surgical interventions for BPH
10. identify the most pertinent adverse events seen in the Women’s Health Initiative and advise patients on the risks and benefits of traditional, non-traditional, and alternative medical interventions for addressing menopausal symptoms

Agenda:
Saturday, October 13, 2007

7:15-7:50 am		Registration, Continental Breakfast and Welcome
7:50-8:10		Welcome Remarks and Pre-Assessment Gregg Sherman, MD
8:10-9:10		Dermatology Therapy Update: Warts, Rosacea and Psoriasis Brian Berman, MD, PhD
9:10-10:10		Update on Statins in the Treatment and Prevention of Cardiovascular Disease: Clinical and Public Health Challenges Charles Hennekens, MD, DrPH
10:10-10:30		Break
10:30-11:30		Fundamentals of Quality Diabetes Care Patrick Boyle, MDA
11:30-12:30		Insulin Therapy in Type 2 Diabetes – Who, When, and How Patrick Boyle, MD
12:30-1:30		Lunch
1:30-2:30		Managing insomnia in 2007 Gary Richardson, MD
2:30-3:30		Restless Leg Syndrome: Diagnosis and Management Gary Richardson, MD
3:30-3:50		Break
3:50-4:50		IBS and Chronic Constipation – Primary Care Update Alin Botoman, MD

Sunday, October 14, 2007

Faculty:
Patrick J. Boyle, MD
Professor of Medicine
University of New Mexico
Albuquerque, NM

Brian Berman, MD, PhD
Professor of Dermatology and Internal Medicine
The University of Miami School of Medicine
Miami, FL

Alin Botoman, MD, FACG, FACP
Gastroenterology Institute of Fort Lauderdale
Clinical Associate Professor of Medicine
University of Miami, Miami, FL

Charles Hennekens, MD, DrPH
Sir Richard Doll Research Professor of Biomedical Science,
Center of Excellence, Florida Atlantic University
Voluntary Professor of Medicine & Epidemiology
and Public Health,
University of Miami Miller School of Medicine
Clinical Professor of Preventive Medicine,
NOVA Southeastern University, Boca Raton, FL

Louis Kuritzky, MD
Clinical Assistant Professor
Department of Community Health & Family Medicine
University of Florida
Gainseville, FL

Walter C. Martinez, MD, FAAN
Director Memory Disorder Center
Director Premiere Research Institute
Associate Clinical Professor of Neurology at Nova Southeastern University
Fort Lauderdale, FL

Gary S. Richardson, MD
Senior Research Scientist
Sleep Research and Disorders Center
Henry Ford Hospital
Detroit, MI

Program Chair: Gregg Sherman, MD

Activity Director: Michelle Frisch, MPH

*Continuing Education Information
This activity has been reviewed and is acceptable for up to 10 Prescribed credit(s) by the American Academy of Family Physicians. The AAFP invites comments on any activity that has been approved for AAFP CME credit. Please forward your comments on the quality of this activity to cmecomment@aafp.org.

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS) and the National Association for Continuing Education. The University of Massachusetts Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Massachusetts Medical School designates this educational activity for a maximum of 10 AMA PRA Category I Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Under the auspices of the University of Massachusetts Medical School Office of Continuing Education this offering meets the requirements for 10 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244- CMR 5.04). Each nurse should claim only those hours of credit that he/she actually spent in the educational activity.

Policy on Faculty and Provider Disclosure: It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidenced- based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

This program was supported through educational grants from the following companies: Amylin, AstraZeneca, Bayer, Boehringer- Ingelheim, Collagenex, Eisai, Merck, NovoNordisk, Sanofi Aventis, Takeda Pharmaceuticals North America, Wyeth.